Early onset metastatic colorectal cancer: current insights and clinical management of a rising condition
B Medici, B Riccò, E Caffari, S Zaniboni, M Salati… - Cancers, 2023 - mdpi.com
Simple Summary In this review, the authors will discuss the highlights of early onset colon
cancer (EOCRC), an increasing but still unclear phenomenon. Indeed, the risk factors are …
cancer (EOCRC), an increasing but still unclear phenomenon. Indeed, the risk factors are …
[HTML][HTML] European expert panel consensus on the clinical management of BRAFV600E-mutant metastatic colorectal cancer
E Martinelli, D Arnold, A Cervantes, S Stintzing… - Cancer Treatment …, 2023 - Elsevier
Metastatic colorectal cancer (mCRC) is a heterogenous disease caused by various genetic
alterations. The BRAF V600E mutation occurs in approximately 8–12% of patients and is …
alterations. The BRAF V600E mutation occurs in approximately 8–12% of patients and is …
Predicting Benefit From FOLFOXIRI Plus Bevacizumab in Patients With Metastatic Colorectal Cancer
MJG Bond, M van Smeden, K Degeling… - JCO clinical cancer …, 2024 - ascopubs.org
PURPOSE Patient outcomes may differ from randomized trial averages. We aimed to predict
benefit from FOLFOXIRI versus infusional fluorouracil, leucovorin, and …
benefit from FOLFOXIRI versus infusional fluorouracil, leucovorin, and …
Primary site and treatment impact in unresectable metastatic colorectal cancer
T Krishnan, F Wang, C Karapetis, A Roy… - Expert Review of …, 2023 - Taylor & Francis
Introduction Colorectal cancer is a heterogenous disease, with various clinical and
molecular subtypes related to the primary site (left versus right colon) of the original tumor …
molecular subtypes related to the primary site (left versus right colon) of the original tumor …
BRAFV600E-Mutant Metastatic Colorectal Cancer: Current Evidence, Future Directions, and Research Priorities
O Piercey, J Tie, F Hollande, HL Wong… - Clinical Colorectal …, 2024 - Elsevier
Abstract BRAF V600E-mutant metastatic colorectal cancer represents a distinct molecular
phenotype known for its aggressive biological behavior, resistance to standard therapies …
phenotype known for its aggressive biological behavior, resistance to standard therapies …
Deep learning for the prediction of the chemotherapy response of metastatic colorectal cancer: comparing and combining H&E staining histopathology and infrared …
Colorectal cancer is a global public health problem with one of the highest death rates. It is
the second most deadly type of cancer and the third most frequently diagnosed in the world …
the second most deadly type of cancer and the third most frequently diagnosed in the world …
GAME-SCORE predicts pathological and radiological response to chemotherapy in patients with colorectal liver metastases
N Russolillo, CC Zingaretti, S Langella… - European Journal of …, 2024 - Elsevier
Abstract Background Genetic And Morphological Evaluation (GAME) score is the newest
prognostic model for patient with colorectal liver metastases (CRLMs). Pathological and …
prognostic model for patient with colorectal liver metastases (CRLMs). Pathological and …
La trichimiothérapie dans les cancers colorectaux métastatiques: pour qui, quand, comment et avec quelles thérapies ciblées?
B Demoustier, T Mazard - Hépato-Gastro & Oncologie …, 2024 - search.ebscohost.com
▼ Abstract In France, colorectal cancer (CRC) remains a public health concern due to its
high incidence and mortality, mostly due to incurable metastatic disease. However, the …
high incidence and mortality, mostly due to incurable metastatic disease. However, the …
[PDF][PDF] Současné možnosti léčby BRAF V600E mutovaného metastatického kolorektálního karcinomu
M Liberko, R Soumarová - Onkologie, 2023 - solen.cz
Metastatický kolorektální karcinom (mCRC) je značně heterogenní onemocnění, u kterého
se prognóza pacientů odvíjí od ne/přítomnosti specifických prognostických a prediktivních …
se prognóza pacientů odvíjí od ne/přítomnosti specifických prognostických a prediktivních …
BRAFV600E Metastatic Colorectal Cancer: Perspective from a Patient, a Caregiver, and an Oncologist
G Gourdin, L Chotel, C de la Fouchardière - Advances in Therapy, 2023 - Springer
This article has been co-authored by a patient with right-sided BRAF V600E metastatic
colorectal cancer (mCRC), his caregiver, and an oncologist. Here the patient and caregiver …
colorectal cancer (mCRC), his caregiver, and an oncologist. Here the patient and caregiver …